LUND, Sweden, June 26, 2020 /PRNewswire/ -- Immunovia AB (publ)
("Immunovia") today announced that the results of the current study
in lung cancer strongly supports an expansion into the next stage
in the discovery process. With the recent capital raise, Immunovia
is fully financed to expand the discovery process in lung cancer.
The next step in the lung cancer program expansion is a study of a
larger cohort of fresh lung cancer samples that best mirrors the
commercial environment.
Lung cancer is by far the leading cause of cancer death among
both men and women. Each year, more people die of lung cancer than
of colon, breast, and prostate cancers combined. About 13% of
all new cancers are lung cancers. With the present lung cancer
program Immunovia aims to be the first that present an opportunity
for an increased overall survival by early detection.
"These results from lung cancer demonstrate that our powerful
technology platform IMMray™ delivers significant robustness in lung
cancer, which further validates our excitement about our platform
that has the potential to revolutionize differential diagnosis for
the early detection of many cancers," stated Mats Grahn, CEO of Immunovia.
Process Overview for Lung Cancer Program
Immunovia's lung cancer study is now in Step 5 of the discovery
process (see figure). As previously guided, a discovery
process often includes several clinical studies, using samples
collected from Immunovia's growing KOL network, before moving to
the development stage.
This is information that Immunovia is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 9:00 CET on
June 26, 2020.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q4
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
For more information, please contact:
Julie Silber
Director of Investor Relations
Immunovia
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-expands-its-lung-cancer-program-based-on-encouraging-results-from-the-current-discovery-st,c3142595
The following files are available for download:
https://mb.cision.com/Main/13121/3142595/1270261.pdf
|
Press release
(PDF)
|
https://news.cision.com/immunovia-ab/i/process-overview-for-lung-cancer-program,c2800638
|
Process Overview for
Lung Cancer Program
|